Semaglutide FDA approval date explained: when Ozempic, Wegovy, and Rybelsus were approved, what each approval covers, and how to verify it in the US.
Semaglutide was first approved by the FDA on December 5, 2017, when the agency cleared Ozempic (semaglutide injection) for adults with type 2 diabetes. Two more brand-name approvals followed: Rybelsus (oral semaglutide) on September 20, 2019, and Wegovy (semaglutide injection for chronic weight management) on June 4, 2021. Since then, the FDA has expanded several semaglutide labels to cover additional uses, including cardiovascular risk reduction.
Semaglutide FDA Approval Dates at a Glance
The table below lists the original FDA approval date for each brand-name form of semaglutide.
| Brand name | Form | FDA approval date | Initial approved use |
|---|---|---|---|
| Ozempic | Semaglutide injection | December 5, 2017 | Type 2 diabetes in adults |
| Rybelsus | Oral semaglutide | September 20, 2019 | Type 2 diabetes in adults |
| Wegovy | Semaglutide injection, 2.4 mg | June 4, 2021 | Chronic weight management |
Ozempic: The First Semaglutide FDA Approval
Ozempic received FDA approval on December 5, 2017, making it the first semaglutide product available in the United States. It was approved as a once-weekly injection to improve blood sugar in adults with type 2 diabetes, alongside diet and exercise.
The approval was based on the SUSTAIN clinical trial program, which showed meaningful A1C reductions compared with placebo and other diabetes medications. Ozempic is not approved for weight loss on its own, although some prescribers use it off-label for that purpose.
Rybelsus and Wegovy: Expanding Semaglutide's Approved Uses
Rybelsus became the first oral GLP-1 receptor agonist approved in the US on September 20, 2019. It offers a daily pill option for adults with type 2 diabetes who prefer not to inject.
Wegovy was approved on June 4, 2021, for chronic weight management in adults with obesity or overweight plus at least one weight-related condition. It uses a higher dose of semaglutide than Ozempic and is given as a weekly injection.
These approvals matter because they define exactly who can be prescribed each product and what claims the manufacturer can make.
Later Label Expansions for Semaglutide
After the initial approvals, the FDA added new indications to semaglutide labels:
- January 2020: Ozempic approved to reduce major cardiovascular events in adults with type 2 diabetes and established heart disease.
- December 2022: Wegovy approved for adolescents aged 12 and older with obesity.
- January 2024: Rybelsus approved to reduce cardiovascular risk in adults with type 2 diabetes and heart disease.
- March 2024: Wegovy approved to reduce cardiovascular risk in adults with obesity or overweight and established cardiovascular disease.
- August 2025: Wegovy approved for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis.
Each expansion required new clinical trial data, and each applies only to the specific brand and population named in the label.
What FDA Approval Does and Does Not Mean
FDA approval means the agency reviewed clinical data and determined that a drug's benefits outweigh its risks for a specific use. It does not mean the drug is safe for everyone, and it does not mean the drug is available without a prescription.
If you are asking is semaglutide fda-approved, the short answer is yes—but only for the indications listed on each product's label. A common question is can i buy semaglutide over the counter; in the US, the answer is no. All semaglutide products are prescription-only.
Semaglutide can cause side effects, including nausea, vomiting, diarrhea, and, rarely, pancreatitis or gallbladder problems. Anyone considering semaglutide should talk with a licensed healthcare professional about personal risks and benefits.
How to Verify Semaglutide FDA Approval Status
To confirm approval details, use the FDA's Drugs@FDA database or the Purple Book. These tools list approval dates, approved indications, and product labeling for every brand-name semaglutide product.
By contrast, retatrutide fda approval has not been granted, and the drug remains investigational. When researchers compare aod 9604 and semaglutide, only semaglutide has an FDA-approved label for human use in the US.
For any injectable medication, the safest place to buy peptides is a licensed US pharmacy that requires a prescription. Buying from unregulated sources increases the risk of counterfeit or contaminated products.
Semaglutide's first FDA approval date was December 5, 2017. Additional approvals followed in 2019 and 2021, and the FDA has continued to expand the label for cardiovascular and liver-related uses. Semaglutide is not FDA-approved for general over-the-counter use, and it is not a cure for any condition. People with questions about semaglutide should consult a healthcare professional before starting treatment.
Frequently Asked Questions
When was semaglutide first FDA approved?
The FDA first approved semaglutide on December 5, 2017, for Ozempic (semaglutide injection) to treat type 2 diabetes in adults. Rybelsus and Wegovy received separate approvals in 2019 and 2021.
Is semaglutide FDA-approved for weight loss?
Yes. Wegovy, a higher-dose injectable form of semaglutide, was approved on June 4, 2021, for chronic weight management in adults with obesity or overweight plus at least one weight-related condition.
Can I buy semaglutide over the counter in the US?
No. All FDA-approved semaglutide products are prescription-only, so you cannot legally buy them over the counter. A licensed healthcare professional must evaluate whether semaglutide is appropriate for you.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.